TokenPost·
Citrini Research Names Charles River, Revvity in AI Drug Thesis
The firm's case rests on faster drug candidate design leading to more laboratory testing, an increase it has not established.
More news
- TokenPostHeartland Express Third-Quarter Revenue Falls 8.7% to $179.5 Million
- TokenPostCross River Parent Agrees to Acquire Accrue Wallet Firm
- TokenPostWeekly AI-Linked CDS Trading Averages More Than $9 Billion
- TokenPostEuropean Gas Futures Retreat Below €90 After Reaching €90.235
- TokenPostAero Merger Replaces Weekly Voting With Revenue-Linked Emissions
- TokenPostMorgan Stanley Keeps Spotify Rating and $640 Target Ahead of Earnings